cognitive cybersecurity intelligence

News and Analysis


GLP-1 agonists: what’s the hype about?

The popularity of Glucagon-like peptide 1 (GLP-1) agonists, drugs which mimic a hormone to stimulate insulin production, has drastically increased since the U.S FDA’s approval of Ozempic in 2017. These drugs can help control type two diabetes by lowering blood sugar when it rises, for example, after meals. However, despite their benefits, these drugs can cause several serious side effects, such as depression and suicidal thoughts. GLP-1’s are also extremely costly, with a monthly supply costing up to $1,350 in America.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts